Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 5, 2014, Pages 296-307

  Liu, Fei ^a,b   Zhuang, Xiaomei ^a   Yang, Cuiping ^a   Li, Zheng ^a   Xiong, Shan ^a   Zhang, Zhiwei ^a   Li, Jin ^a   Lu, Chuang ^c   Zhang, Zhenqing ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b Department of Pathology First Affiliate Hospital of PLA   (China)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

allometric scaling; dopamine D3 receptor antagonist; in vitro ADME; PBPK; YQA 14

Indexed keywords

DOPAMINE 3 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; YQA 14; BENZOXAZOLE DERIVATIVE; DOPAMINE 3 RECEPTOR; PIPERAZINE DERIVATIVE; YQA14;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CLEARANCE; LIVER CYTOSOL; LIVER MICROSOME; MALE; NONHUMAN; PHARMACOKINETICS; PKA; PLASMA CONCENTRATION-TIME CURVE; RAT; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BIOLOGICAL MODEL; DOG; METABOLISM; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; VALIDATION STUDY;

ANIMALS; BENZOXAZOLES; BIOLOGICAL AVAILABILITY; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D3; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84904048476     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1897     Document Type: Article

References (38)

1. Koob GF, Le Moal M,. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52-58. (Pubitemid 27446270)
2. Le Moal M, Koob GF,. Drug addiction: pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol 2007; 17: 377-393. (Pubitemid 46497657)
3. Caine SB, Koob GF,. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993; 260: 1814-1816.
4. Heidbreder CA, Andreoli M, Marcon C, et al., Role of dopamine D3 receptors in the addictive properties of ethanol. Drugs Today (Barc) 2004; 40: 355-365. (Pubitemid 38724778)
5. Heidbreder CA, Gardner EL, Xi ZX, et al., The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 2005; 49: 77-105. (Pubitemid 40800164)
6. Le Foll B, Schwartz JC, Sokoloff P,. Dopamine D3 receptor agents as potential new medications for drug addiction. Eur Psychiatry 2000; 15: 140-146. (Pubitemid 30194159)
7. Burris KD, Pacheco MA, Filtz TM, et al., Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology 1995; 12: 335-345.
8. Pilon C, Lévesque D, Dimitriadou V, et al., Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol 1994; 268: 129-139.
9. Di Ciano P, Underwood RJ, Hagan JJ, Everitt BJ,. Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 2003; 28: 329-338.
10. Micheli F, Heidbreder C,. Dopamine D3 receptor antagonists: a patent review (2007-2012). Expert Opin Ther Pat 2013; 23: 363-381.
11. Mason CW, Hassan HE, Kim KP, et al., Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. J Pharmacol Exp Ther 2010; 333: 854-864.
12. Orio L, Wee S, Newman AH, Pulvirenti L, Koob GF,. The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addict Biol 2010; 15: 312-323.
13. Gilbert JG, Newman AH, Gardner EL, et al., Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 2005; 57: 17-28. (Pubitemid 40756331)
14. Austin NE, Baldwin SJ, Cutler L, et al., Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011A in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 2001; 31: 677-686. (Pubitemid 32826399)
15. Xi ZX, Gardner EL,. Pharmacological actions of NGB2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev 2007; 13: 240-259. (Pubitemid 47052351)
16. Song R, Yang RF, Wu N, et al., YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol 2012; 17: 259-273.
17. Avdeef A,. pH-Metric log P. Part 1. Difference plots for determining ion-pair octanol-water partition coefficients of multiprotic substances. Quant Struct-Act Relat 1992; 11: 510-517. (Pubitemid 23035429)
18. Stopher D, McClean S,. An improved method for the determination of distribution coefficients. J Pharm Pharmacol 1990; 42: 144. (Pubitemid 20238649)
19. Liu F, Zhao Y, Sun J, Gao Y, Zhang Z,. Formulation and evaluation of thienorphine hydrochloride sublingual delivery system. Chem Pharm Bull 2012; 60: 1479-1486.
20. Walker DK, Abel S, Comby P, et al., Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005; 33: 587-595. (Pubitemid 40393203)
21. Houston JB,. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479. (Pubitemid 24167255)
22. Obach RS, Baxter JG, Liston TE, et al., The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46-58. (Pubitemid 27438945)
23. Hosea NA, Collard WT, Cole S, et al., Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009; 49: 513-533.
24. Rodgers T, Rowland M,. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95: 1238-1257. (Pubitemid 43874439)
25. Reagan-Shaw S, Nihal M, Ahmad N,. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661. (Pubitemid 351348146)
26. Davies B, Morris T,. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095. (Pubitemid 23211439)
27. Paixão P, Gouveia LF, Morais JA,. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model. Int J Pharm 2012; 429: 84-98.
28. Kararli TT,. Gastrointestinal absorption of drugs. Crit Rev Ther Drug Carrier Systems 1989; 6: 39-86. (Pubitemid 19189426)
29. Kararli TT,. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995; 16: 351-380.
30. Persson EM, Gustafsson AS, Carlsson AS, et al., The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 2005; 22: 2141-2151. (Pubitemid 41821594)
31. Rostmi-Hodjegan A,. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 2012; 92: 50-61.
32. Rostami-Hodjegan A, Tucker GT,. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Dis 2007; 6: 140-148. (Pubitemid 46745341)
33. Lu C, Li P, Gallegos R, et al., Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans, evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 2006; 34: 1600-1650.
34. De Buck SS, Sinha VK, Fenu LA, et al., Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35: 1766-178.
35. Yu LX, Amidon GL,. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999; 186: 119-125. (Pubitemid 29459038)
36. Agoram B, Woltosz WS, Bolger MB,. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 (Suppl 1): 41-67.
37. Hörter D, Dressman JB,. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001; 46: 75-87.
38. Heidbreder CA, Gardner EL, Xi ZX, et al., The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 2005; 49: 77-105. (Pubitemid 40800164)